ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Manhattan Scientifics Inc (PK)

Manhattan Scientifics Inc (PK) (MHTX)

0.00165
0.00045
(37.50%)
Closed April 28 4:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.00165
Bid
0.0012
Ask
0.002
Volume
106,973
0.0012 Day's Range 0.0018
0.0012 52 Week Range 0.0089
Market Cap
Previous Close
0.0012
Open
0.0012
Last Trade
100
@
0.00165
Last Trade Time
Financial Volume
$ 189
VWAP
0.001765
Average Volume (3m)
180,916
Shares Outstanding
559,281,064
Dividend Yield
-
PE Ratio
0.00
Earnings Per Share (EPS)
-0
Revenue
-
Net Profit
-1.17M

About Manhattan Scientifics Inc (PK)

Sector
Electrical Machy, Equip, Nec
Industry
Electrical Machy, Equip, Nec
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Manhattan Scientifics Inc (PK) is listed in the Electrical Machy, Equip sector of the OTCMarkets with ticker MHTX. The last closing price for Manhattan Scientifics (PK) was $0. Over the last year, Manhattan Scientifics (PK) shares have traded in a share price range of $ 0.0012 to $ 0.0089.

Manhattan Scientifics (PK) currently has 559,281,064 shares outstanding. Manhattan Scientifics (PK) has a price to earnings ratio (PE ratio) of 0.00.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-5.0E-5-2.941176470590.00170.00180.00123597350.00147624CS
4-0.0014-45.90163934430.003050.003050.00123261890.00162552CS
12-0.00075-31.250.00240.00520.00121809160.00231273CS
26-0.00225-57.69230769230.00390.00520.00121595880.00270036CS
52-0.0036-68.57142857140.005250.00890.00121262360.00345948CS
156-0.02915-94.64285714290.03080.040.00121343440.01395366CS
260-0.01435-89.68750.0160.050.00122194970.01951266CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

MHTX Discussion

View Posts
ssc ssc 2 months ago
Nothing from you since your last brilliant due diligence on ibx new ceo who only lasted a few months before resigning. mhtx under 1/2 of a penny, ibx down to 8 cents after reverse split...hope you are ok and didn't die of embarrassment. mhtx, ibx, ntek - one hell of a trifecta lmao.
πŸ‘οΈ0
ssc ssc 2 months ago
Anyone still following Imagion? New ceo left after only a few months on board; now the cfo is bailing. Rats jumping off proulx's sinking ship. Lost $13 million last year and less than $250,000 in cash left. Shares already down to 8 cents after reverse split. This last statement from ibx's latest news release sums it all up:

Given the lack of liquidity and staff reductions the consolidated entity has paused all other research and
development activities including proceeding towards an IND filing for its MagSense HER2 Breast Cancer program.
πŸ‘οΈ0
ssc ssc 3 months ago
ibx "new" ceo already out the door. Looks like it didn't take him long to see how bad this mess is. And guess who is back in the driver's seat? Good old Lake Tahoe Bobbie. So discontinue the "human instrument" after a decade of wasted time and $millions of wasted money, take share price from 20 cents to near zero, reverse split the shares, hire new ceo to save the day, suffer more embarrassment as new ceo leaves after a few months, and proulx back as ceo. Meanwhile no cash to do any of the things that have been promised going as far back as the original manny and marv scam that began so many years ago.

Any more great videos or articles?
👍️ 1
rustydog62 rustydog62 5 months ago
πŸ‘οΈ0
ssc ssc 5 months ago
How exciting was this statement:
The Company continues to work towards its Investigational New Drug application for submission to the US FDA, which was initially planned for Q1:2024, but now likely to be delayed as Imagion works to ensure sufficient resources are in place to pursue clinical development of the MagSense imaging technology.
You don't need a magsense machine to find the coming dilution in that statement. So some good news on the technology side, same old bad story for those who bought in during the manny/marv/proulx era and recently suffered the 1:40 reverse split
πŸ‘οΈ0
rustydog62 rustydog62 5 months ago
Exciting news! 🌟 Tomorrow at 7 am CST, Imagion presents groundbreaking data from our IBI10103 Phase I Study demonstrating the safety and clinical feasibility of Molecular MRI with #MagSense HER2 Imaging Agentat #SABCS23. Request the data: https://t.co/FNCdufN13G #Innovation $IBX pic.twitter.com/oS2rSuhWRC— Manhattan Scientific (@mhtxscientifics) December 6, 2023
πŸ‘οΈ0
WHITTENHALLJR WHITTENHALLJR 5 months ago
Yes sinking fast! Maybe will get trips?
πŸ‘οΈ0
MattyTrader MattyTrader 5 months ago
This is going to 000s
πŸ‘οΈ0
ssc ssc 5 months ago
How low can you go? How does $.0034 sound?
πŸ‘οΈ0
rustydog62 rustydog62 5 months ago
https://www.researchgate.net/publication/373758125_Limited_input_metal_balance_optimization_LIMBO_how_low_can_you_go
πŸ‘οΈ0
ssc ssc 5 months ago
Reality check to rustydog - how about an update on that metals deal? You know, the latest scheme that put hundreds of thousands of dollars into the hands of manny and marv. Where did all that cash go? The only things shareholders know is it must have paid for a lot of trips to the lobster buffet.

You were so high on the metals deal, and now not a peep. Must be quite embarrassing to support manny and marv on one scheme after another and end up with sub-penny garbage.
πŸ‘οΈ0
ssc ssc 6 months ago
Once ibx comes out with their version (if that ever happens) current shares will be diluted to worthlessness. mhtx shareholders will gain nothing from all the manny and marv years of promises, hype and lobster dinners.

By the way rustydog, how is that metals deal coming along? lmao.
πŸ‘οΈ0
rustydog62 rustydog62 6 months ago
Once IBX comes out with their version there will be no misdiagnosed views...

"Despite Prenuvo's focus on preventive health, many radiologists say full-body MRI scanning can do more harm than good. False positives and detection of benign abnormalities could send patients down a path of unnecessary follow-up tests and interventions." Aug 18, 2023
πŸ‘οΈ0
ssc ssc 6 months ago
Interesting MRI cancer diagnostic company that actually has something that works technically and commercially. If only manny, marv, proulx had spent the last 10 years as successfully as Prenuvo did. Interesting read:

https://www.cnbc.com/2023/11/10/prenuvo-offers-2500-full-body-mri-scans-that-can-detect-cancer-early.html

Maybe new ibx ceo should be trying to partner with them or, better yet sell the whole thing and let someone who seems to know what they are doing take over.
πŸ‘οΈ0
ssc ssc 6 months ago
Healthy presentation. Hmmmm. Have you seen his presentation of the upcoming 1:40 reverse split? All long time shareholders say bye bye to your investment. Ditto for scammers manny and marv and sucker mhtx shareholders. Can't wait to see how anyone tries to put lipstick on this one.
πŸ‘οΈ0
rustydog62 rustydog62 6 months ago
A healthy new presentation by new IBX CEO here...

πŸ‘οΈ0
hunchboy hunchboy 8 months ago
Ok nvnt has new name and looks to 4xthis week. 10cents
πŸ‘οΈ0
MattyTrader MattyTrader 8 months ago
Either a nice bottom buy or this is another scam POS ticker everyone is underwater on
πŸ‘οΈ0
gorcon gorcon 9 months ago
Some interesting news:
Imagion Biosystems partnering with Prestige Biopharma to develop pancreatic cancer diagnosis platform
πŸ‘οΈ0
Ecomike Ecomike 10 months ago
Well I hope the weak hands keep selling down here cheap while my team loads up the fleet with these shares. Had this stock on My radar for ages, and I finally started buying Monday.

This is so over sold it is nuts. Just needs volume and eyes. A problem I can solve with the historical news. The FED beat to a pulp Market has brought us so many bargains...
πŸ‘οΈ0
rustydog62 rustydog62 10 months ago
https://imagionbiosystems.com/news/imagion-expands-collaboration-with-siemens-healthineers-to-united-states/
πŸ‘οΈ0
Sparroww Sparroww 10 months ago
I enjoyed reading this release https://investorhub.imagionbiosystems.com/announcements/4372071

A little too late for me as I sold my position, with a new CEO, this may be worth looking at in the future.. as usual Bob creates press release that can bore folks to sleep.. so here is a simple explanation.

Imagion Biosystems, a company dedicated to earlier cancer detection, said that they've achieved their goals for their first clinical study, the MagSense® HER2 breast cancer Phase 1 study, and are preparing to close the study by July 31, 2023.

What does this mean?

Well, they've developed this cool, new technology that can help change how we use MRI to spot cancer. It's like a special contrast agent that makes it easier to see cancer on an MRI image. Some independent experts in radiology checked out their work and agree that it's really promising!

So what's next?

With the success of this study, Imagion is now set to prepare a submission for a larger, multi-site Phase 2 trial in the U.S., which they hope to start by the end of 2023 or early 2024. But before they do that, they'll be making more of their special MagSense® HER2 imaging agent and completing some additional studies following the FDA's guidance.

They also plan to recruit a few more patients to test a new method of imaging after the cancerous nodes have been removed from the body. This might help them to correlate MRI findings with pathology in the upcoming Phase 2 study.

All this will take time and Lot$$$ of money and probably further dilution.

Good luck to all those still in the stock.
πŸ‘οΈ0
ssc ssc 11 months ago
lol, my bad. I forgot how far this stock has fallen. Triple zeros on the way?
πŸ‘οΈ0
Drooling Drooling 11 months ago
MHTX has been sub-penny for months. I'll take odds on MHTX.
πŸ‘οΈ0
ssc ssc 11 months ago
Which goes sub-penny first, mhtx or ibx? Manny, marv, proulx, lock them up.
πŸ‘οΈ0
ssc ssc 11 months ago
Here's an investor update: mhtx .0035, ibx .01

Anyone spoken with manny or marv lately? Lock them up. Proulx bailing after wasting so many years and $millions - but ain't life great at Lake Tahoe?
πŸ‘οΈ0
ssc ssc 12 months ago
No one mentioning proulx baling out after taking ibx share price from 20 cents to a penny, running the Phase 1 drug trial that never ends, and diluting shareholders into oblivion. Too bad he wasn't shown the door years ago.
πŸ‘οΈ0
MattyTrader MattyTrader 12 months ago
Wtf someone dumping huge at open
πŸ‘οΈ0
hunchboy hunchboy 12 months ago
You trust the Marv? I hot a vaccine for you
πŸ‘οΈ0
ssc ssc 1 year ago
Any update on the metals deal? manny and marv sucked every cent out of mhtx investors and burned thru all the $millions that came in over the years. When was the last time either one communicated with shareholders? Lock them up.
πŸ‘οΈ0
ssc ssc 1 year ago
Seems odd for anyone to claim a stock is being shorted when it is under a penny. There are no reports of a large amount of mhtx short positions. The time to short mhtx would have been when it traded near 17 cents, not after it has lost almost all of its value.

What is the price of this other stock you claim "the big short seller" is shorting? Any proof regarding these large short positions?
πŸ‘οΈ0
Krombacher Krombacher 1 year ago
Guys,

The big short seller shorting this issue is about to get obliterated financially in another stock he is shorting.

Take advantage of that guys.

Krombacher
πŸ‘οΈ0
MattyTrader MattyTrader 1 year ago
They haven’t even diluted in the last year +
πŸ‘οΈ0
ssc ssc 1 year ago
There is nothing left to see. Even manny and marv don't say anything about the company anymore. Out of cash, out of scam deals, out of gullible buyers. Lock them up, they've enjoyed life financed by trusting investors long enough.
πŸ‘οΈ0
MattyTrader MattyTrader 1 year ago
Got pretty ugly here… may lose OTCQB if they don’t get back over .01 soon
πŸ‘οΈ0
ssc ssc 1 year ago
Proulx strikes out again. Wanted to raise $2.5 million from existing shareholders at $.017 but got less than $500,000. Looks like his new direction (the one without a magsense instrument) isn't being received too well. So now what? Like I predicted, $millions more will most likely have to be raised at less than a penny USD. What a shameful display of incompetence while living it up at Lake Tahoe.
πŸ‘οΈ0
ssc ssc 1 year ago
Point is, even a paid promoter thinks it would be great if ibx reached 3 or 4 cents again. Proulx's new direction wiped out any chance of ever seeing 10 or 20 cents again.
πŸ‘οΈ0
Sparroww Sparroww 1 year ago
I always hated and will always hate paid reports. So unbiased.lol

"Readers should be aware that Pitt Street Research Pty Ltd has been engaged and paid by the company covered in this report for ongoing research coverage."
πŸ‘οΈ0
ssc ssc 1 year ago
"We value Imagion at $83.1m in our base case and $126.7m
in our optimistic case using a DCF approach. This equates to
3.6c per share and 5.5c per share respectively taking into
account anticipated dilution in the next few years."
πŸ‘οΈ0
rustydog62 rustydog62 1 year ago
Investors update

Newsletter Highlights:

Clinical data and expert review triggers commercial partner outreach efforts
MRI utility drives new IP and AI/ML efforts
Upcoming events and a recap on key media coverage
A Message From the CEO
As we noted in our 2022 Annual Report, last year was a momentous year having reported results from the first cohort of subjects in the MagSense® HER2 Phase 1 study at a global breast cancer meeting and presenting our prostate cancer imaging agent at an imaging conference.


That momentum has continued in the first quarter of this year with the independent review we reported at the beginning of February and the recent news of our communications with the FDA related to our plans to file an IND and proceed with a multi-site study in the U.S. for the MagSense® HER2 imaging agent.


In this newsletter, we are pleased to share some of the additional activities we are undertaking to keep the momentum going.


We look forward to keeping all our stakeholders apprised of the work we are doing to change the way we look at cancer with our MagSense® molecular imaging technology.

Bob Signature 600px (2)
Strategic Partnering Data Room
Our MagSense® imaging agents could be the first-of-its-kind molecular imaging solution for MRI. By changing current practice in medical imaging to include the sensitive and selective detection of cancer cells without using radiation, Imagion’s technology could significantly improve cancer diagnosis and patient care.


Now that our MagSense® imaging agent for HER2 breast cancer detection is progressing towards Phase 2 and our technology is showing positive preclinical results in other areas of high unmet need, including prostate cancer and ovarian cancer, we have a substantial value proposition for the medical imaging sector and are now well-placed to initiate discussions around strategic options with potential commercial partners. Our current pipeline represents a projected global market opportunity of ~ $5Billion* for Imagion and our partner(s).

To facilitate the process, we have established a secure data room where we can share confidential information related to the MagSense® HER2 program as well as our growing pipeline of imaging agents and will begin outreach programs to potential partners in an effort to gauge market interest in our technology.


Parties interested in partnering with Imagion to commercialize our MagSense® molecular imaging technology can contact us via partnering@imagionbio.com.


* Total available market estimates based on market data of current testing and a projected MagSense® price of $1200.

MRI Utility Drives New Areas for IP and Analytics
Data from the MagSense® HER2 Phase 1 study and internal R&D programs have opened new opportunities for Imagion to file for intellectual property and are driving efforts to investigate how analytical methods in Artificial Intelligence (AI) and Machine Learning (ML) might be applied to improve the clinical utility of the MagSense® imaging tests.

A provisional patent application has been filed related to the image pattern(s) associated with presence of the MagSense® targeted imaging agent. This new IP would extend our proprietary position for our magnetic nanoparticles across both magnetic relaxometry and magnetic resonance imaging, providing broader protection against other imaging agents that might try to replicate targeted detection by MRI. While there is no guarantee that the patent will issue, the new IP would provide significant value to Imagion and its commercial partners, carving out a unique space in the medical imaging landscape.

Additionally, the Company has initiated a project with a 3rd party with expertise in image analysis methods including AI and ML, to determine if algorithmic solutions could be applied to the MRI scans resulting from a MagSense® test to improve interpretability. Data from the Phase 1 study has informed the initial investigations and the Company is now looking into how algorithmic solutions may help drive improvements in image acquisition in the Phase 2 study. If algorithmic solutions can be applied, it would open the opportunity for the MagSense® imaging agents to be sold with an associated Software as a Medical Device (SaaMD) solution to aid radiologists in the interpretation of the MagSense® test results.


Since all MagSense® targeted imaging agents use the same underlying magnetic nanoparticle technology, the Company would look to apply the intellectual property and image analysis solutions broadly across the portfolio of MagSense® nanoparticle imaging agents.
πŸ‘οΈ0
rustydog62 rustydog62 1 year ago
https://imagionbiosystems.com/news/pitt-street-research-april-2023/
πŸ‘οΈ0
lovemelongtime lovemelongtime 1 year ago
I have confidence in Manny and Marv. A constant battle with this company being shorted so heavily though.
πŸ‘οΈ0
ssc ssc 1 year ago
Any word from manny and marv on the latest dead metals fiasco?

Any videos from proulx on when ibx outstanding shares will hit 2 billion?
πŸ‘οΈ0
northside1 northside1 1 year ago
Looks like you might not have understood my point. It is that CMS stating that a nanostructured variant of Ti-13Zr will soon become available does not mean Ft. Wayne Metals and MHTX are involved. The entity that will make it available is not specified. MHTX owns a patent on a process. The end product, nanostructured titanium, is not patentable. MHTX has stated that.
πŸ‘οΈ0
ssc ssc 1 year ago
Hard to believe anyone is still clinging to the fantasy that this company will actually deliver anything of value. manny and marv have been milking this company for more than 20 years. Look at the press release history on mhtx website - one undelivered promise after another. Look at a stock chart - 17 cents to below a penny. Look for honest communications from them - none to be found.

Nano-Ti dental implants? The only one is rotting in Terry Lowe's mouth.

Amazing Magsense machine 1000 times more sensitive than a mammogram? Proulx finally put it to rest at the bottom of Lake Tahoe.

Lock them up.
πŸ‘οΈ0
northside1 northside1 1 year ago
Could this be the Ti-13Zr variation (Ti-13Nb-13Zr) mentioned in the CSM website? Hexon Metal Technology is the manufacturer.
http://www.hexonmetal.com/13nb-13zr-p-54.html
Typical applications
Surgical implants
πŸ‘οΈ0
ssc ssc 1 year ago
Where are manny and marv? Are they still alive? Haven't seen an update, p/r or shareholder meeting in a long time. Maybe moved offshore to avoid any possible prosecution or clawback for all the years of misleading investors and financing their own lifestyles with mhtx cash?

And proulx can't be far behind. After all these years forced to raise $millions with ibx share price struggling to hold above a penny. Despicable and shameful. His new direction for the company should result in a new direction for him out the door.
πŸ‘οΈ0
Drooling Drooling 1 year ago
Poor Marv

Always the bridesmaid, never the bride.

He held on to Flynn's technology for so long before he tried to spin it off that it's been grounded before it ever flew.

β€˜Holy grail’ of cancer detection predicts tumors a year before they form: breakthrough

In a trial of 1,000 participants β€” 500 non-cancer and 500 cancer patients β€” researchers were able to accurately anticipate the formation of tumors across at least 25 types of cancer, including all of the most prevalent and deadly varieties, such as breast, pancreatic, lung and colorectal. Even some participants within the presumed β€œnon-cancer” group were found to have a predisposition for future cancer diagnosis.

https://nypost.com/2023/03/27/holy-grail-of-cancer-detection-predicts-tumors-a-year-before-they-form-breakthrough/

How's the metal squashing business going since Carpenter trashed it? It disappeared down some other company's bad-investment-rathole. Governments across the globe are investing hundreds of billions into their high-voltage infrastructure. Where's MHTX? Still squarshing away in some lab somewhere with 70 year old Soviet technology.
πŸ‘οΈ0
ssc ssc 1 year ago
Just realized the price ihub is quoting for ibx is in Australian $'s. The U.S. price is about a penny. The newest slap in the face from lake tahoe proulx is raising cash at $.011/share. And that's for current shareholders. If everyone participated it would raise less than $2 million and add about 150 million shares of dilution. Of course proulx will need a lot more than $2 million to do the next trial and that cash will most likely be raised at less than a penny/share. Anyone feel free to correct me if these estimates are way off.

Any new links to proulx promo videos? So sad.
πŸ‘οΈ0
ssc ssc 1 year ago
To any of the proulx fans out there, how long until ibx under a penny? Any links to new proulx promo interviews? Notice how he never mentions the share price or how many $millions needed for the next trial. Small time ceo, big time dilution. But isn't life great at Lake Tahoe?
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock